statin treatment and amlodipine

Last reviewed 04/2023

The MHRA Drug Safety Update (August 2012) highlights changes to the simvastatin SmPC regarding interactions that can increase the risk of myopathy and/or rhabdomyolysis.

When used with amlodipine, the maximum dose of simvastatin is now 20mg; higher doses are 'off-label'. For patients taking amlodipine and simvastatin 40mg consider:

• 1. reducing simvastatin dose to 20mg - most patients can be managed this way as the interaction with amlodipine leads to an increase in simvastatin exposure that is similar to taking simvastatin 40mg alone.
  
  
• 2. Staying on simvastatin 40mg - discuss the risks and benefits of this 'off-label' option with the patient. Be aware that, due to the interaction with amlodipine, exposure to adverse effects is similar to that associated with simvastatin 80mg when given alone
  
  
• 3. Change to an alternative statin
  • pravastatin, fluvastatin or rosuvastatin do not interact with amlodipine
  • atorvastatin (20mg or 40mg daily) is an option if a more potent statin is needed. The risk of an interaction with amlodipine is much lower with atorvastatin than simvastatin
    
    
• 4. Change to an alternative calcium channel blocker - do not change therapy in patients who are well controlled with amlodipine. Altering the calcium channel blocker is clinically less desirable. Note: the maximum dose of simvastatin is also 20mg with verapamil and diltiazem.

Consider each patient individually taking into account:

• multiple drug therapy and the possibility of drug interactions,
• co-morbidities, including liver function,
• following a change in therapy monitor patients for efficacy and adverse effects

Pharmokinetics of interaction:

• simvastatin is metabolised by the cytochrome P-450 isoenzyme CYP3A4 and is very sensitive to the effects of CYP3A4 inhibitors, leading to many well recognised drug interactions
• amlodipine is a weak inhibitor of CYP3A4
• concurrent use of amlodipine and simvastatin causes a significant increase in blood levels of simvastatin such that, in practice, the effect is double that compared to uninhibited simvastatin. Therefore, in patients on amlodipine 10mg plus simvastatin 20mg, the effect is similar to receiving simvastatin 40mg alone. The same applies for higher doses of simvastatin where the risk of adverse effects is much greater
• fluvastatin, pravastatin and rosuvastatin are not metabolised by CYP3A4 to any significant extent and they do not interact with amlodipine.
• atorvastatin is also metabolised by CYP3A4 but is less susceptible to interaction with CYP3A4 inhibitors than simvastatin due to its structure. No clinically significant interaction between amlodipine and atorvastatin has been reported
• Verapamil and diltiazem are known inhibitors of CYP3A4; the maximum dose of simvastatin is 20mg daily in patients taking these. Other calcium channel blockers do not interact with simvastatin

Reference:

• 1) MHRA Drug Safety Update (August 2012). Simvastatin: increased risk of myopathy at high dose (80 mg)